Addlife Ab Class B · OMXSTO:ALIF_B
Addlife Ab Class B — Q2 2023 Earnings Presentation
17 slides from Addlife Ab Class B's earnings presentation, Jul 14, 2023
Slide 1: Interim report AddLife
INTERIM REPORT Q2 2023 Interim report AddLife July 14, 2023
Slide 2: Continued strong growth
INTERIM REPORT Q2 2023 Continued strong growth • Strong development in all parts of the business, 14% revenue growth Organic, currency adjusted growth 9% in Labtech, 8% in Medtech • Increased activity in elective surgery continues, significant backlog remains • Commercial activities in full force
Slide 3: Net Sales & EBITA Q2
INTERIM REPORT Q2 2023 Net Sales & EBITA Q2 Net sales • Net Sales SEK 2,365m: +14% • COVID-19 sales SEK 0m: -100% • Organic currency adjusted growth excl. COVID-19: +8% EBITA • EBITA: SEK 247m +3% • EBITA margin: 10.4% (11.6) • Investments in digital solutions amounted to SEK 15m (17)
Slide 4: EBITA-margin post COVID-19
INTERIM REPORT Q2 2023 EBITA-margin post COVID-19 • In Labtech COVID-19 sales that contributed EBITA-marginal % to margin have ceased, partially countered by 30% strong organic growth 25% 20% Margin remains above the previous 15% 12.2% range of 10-12% 10% 5% 9.7% • Strong revenue development in Me
Slide 5: Labtech Q1
INTERIM REPORT Q2 2023 Labtech Q1 • Organic currency adjusted growth +9% • COVID-19 related sales now behind us (LY SEK 36m) • Developing the portfolio, introducing new products • Active price management, protecting margins 872 107 12.2 39 807 Net Sales SEKm EBITA SEKm EBITA margin % No of No of +11
Slide 6: Labtech – Organic growth, developing portfolio
INTERIM REPORT Q2 2023 Labtech – Organic growth, developing portfolio Diagnostics Biomedical and Research • Solid growth • Strong growth • Testing volumes benefit from hospital activity • Academic research demand somewhat cautious in some markets, primarily • Strong market position based on product
Slide 7: Medtech Q2
INTERIM REPORT Q2 2023 Medtech Q2 • Strong organic, currency adjusted growth: +8% • Health care markets recovering, significant increase in elective surgery • Increase in sales and marketing activities, selectively strengthening sales teams • Adding significant new supply agreements 1.496 145 9.7 50
Slide 8: Medtech – Increased activity in surgery
INTERIM REPORT Q2 2023 Medtech – Increased activity in surgery Hospital/Health services Homecare • Elective surgical procedures increasing across • Healthy revenue development in home care products Europe – long term trend continues • All hospital focused companies performing very • Homecare portfol
Slide 9: Market trends and implications
INTERIM REPORT Q2 2023 Market trends and implications Market trends: current and expected Post pandemic environment: Staffing shortage, hospital capacity Outcome & efficiency Elective surgery recovering constraints focused healthcare spending Distributor consolidation Suppliers restructuring, focusi
Slide 10: Distribution - Growth Opportunities (Euroclone and MGI)
AddLife® Distribution - Growth Opportunities Division: Clinical testing & laboratory equipment | Territory:Italy & Nordics RIG! CASE STUDY ( >) Euroclone signed a multi-year distribution contract with MGI, an industry leading provider of transformativ! cology and surgical pr ict portfolio. AddLife c
Slide 11: Distribution - Growth Opportunities (HC21 and AngioDynamics)
AddLife® INTERIM REPORT Q2 2023 Distribution - Growth Opportunities Division: Innovation oncolegy & products | Territory: UK & Ireland, Denmark, Benelux countries ( >) MED! (AS HC21 signed a multi-year distribution contract with AngioDynamics, an industry leading provider of transformative oncology
Slide 12: Profit & Loss Q2
INTERIM REPORT Q2 2023 Profit & Loss Q2 • Strong growth, +14% • Gross margin stable thanks to product mix and price management, but under pressure • Increased commercial activities and strenghthened sales organization • Increased interest costs
Slide 13: Cash flow Q2
INTERIM REPORT Q2 2023 Cash flow Q2 • Cash flow used to finance growth • A/R & inventory increase with revenue • Introduction of new suppliers and products WC -131 • Buffer inventory due to component shortages • Continuous focus on cash generation • Structured process that will take some time
Slide 14: Medtech is the largest business area
INTERIM REPORT Q2 2023 Medtech is the largest business area WC / revenue Revenue MSEK and % share Share of total: 35% 33% 6,000 61% 30% 27% 5,000 25% 22% 22% 22% 4,000 39% 20% 18% Share of total: 3,000 15% 63% 2,000 10% 37% 5% 1,000 0% 0 1906 2306 1906 2306 Medtech Labtech AddLife Medtech MSEK Labte
Slide 15: Summary
INTERIM REPORT Q2 2023 Summary • Strong market positions, solid growth in all parts of the business • Sales and marketing activities back to full scale, selectively strengthened commercial teams • Expanding the product portfolio with advanced products • EBITA increased Protecting margins, fewer pr
Slide 16: Capital Markets Day
INTERIM REPORT Q2 2023 Capital Markets Day Date: September 15th Time: 08.30 AM CEST Location: Studio Puck, Kommendörsgatan 24 or online Welcome investors, analysts, and financial media to our Hybrid Capital Markets Day on September 15, 2023. The purpose of the Capital Markets Day is to give insights
Slide 17: Q&A
INTERIM REPORT Q2 2023 Q&A Fredrik Dalborg CEO +46 705 16 09 01 fredrik.dalborg@add.life Christina Rubenhag CFO +46 705 46 72 22 christina.rubenhag@add.life